Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura
Clin Mol Hepatol. 2022;28(2):269-272.   Published online 2022 Feb 15     DOI: https://doi.org/10.3350/cmh.2022.0040
Citations to this article as recorded by Crossref logo
Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications
Jie Fang, Chen-Huan Yu, Xue-Jian Li, Jin-Mei Yao, Zheng-Yu Fang, Soo-Hyun Yoon, Wen-Ying Yu
Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma
Shigeo Shimose, Atsushi Hiraoka, Andrea Casadei‐Gardini, Tsubasa Tsutsumi, Dan Nakano, Hideki Iwamoto, Fujimasa Tada, Margherita Rimini, Masatoshi Tanaka, Takuji Torimura, Hideya Suga, Hideko Ohama, Valentina Burgio, Takashi Niizeki, Etsuko Moriyama, Hiro
Hepatology Research.2022;[Epub]     CrossRef
Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis
Tanat Yongpisarn, Amornrut Namasondhi, Wimolsiri Iamsumang, Ploysyne Rattanakaemakorn, Poonkiat Suchonwanit
Frontiers in Medicine.2022;[Epub]     CrossRef